Back to Search
DAVID W DRUCKER MD
MD
Interventional Cardiology Physician
NPI: 1730179854IndividualAccepts Medicare
Specialties, Licenses & Credentials
Interventional Cardiology PhysicianPrimary
Internal Medicine — Interventional Cardiology
Code: 207RI0011X
25MA06893300(NJ)MD067523L(PA)
Education
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1990
Research & Publications (20)
Distinguishing conjoint and independent neural tuning for stimulus features with fMRI adaptation.
PMID 19357342·J Neurophysiol·2009
8-other
Different spatial scales of shape similarity representation in lateral and ventral LOC.
PMID 19176637·Cereb Cortex·2009
8-other
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
PMID 18782641·Lancet·2008
2-rct
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
PMID 17337495·Diabetes Care·2007
6-review
Enhancing the action of incretin hormones: a new whey forward?
PMID 16777979·Endocrinology·2006
7-preclinical
Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?
PMID 16929370·Nat Clin Pract Endocrinol Metab·2005
8-other
Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis.
PMID 14645210·Endocrinology·2003
6-review
Enhancing incretin action for the treatment of type 2 diabetes.
PMID 14514604·Diabetes Care·2003
6-review
Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.
PMID 12554744·Mol Endocrinol·2003
6-review
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
PMID 12517256·Expert Opin Investig Drugs·2003
6-review
Biological actions and therapeutic potential of the glucagon-like peptides.
PMID 11832466·Gastroenterology·2002
6-review
Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
PMID 11472275·Curr Pharm Des·2001
6-review
New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.
PMID 11193827·Ann N Y Acad Sci·2000
6-review
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
PMID 18801896·Endocrinology·2009
7-preclinical
Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse.
PMID 18845625·Endocrinology·2009
7-preclinical
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action.
PMID 19008308·Endocrinology·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 104 PHEASANT RUN, SUITE 128
NEWTOWN, PA 18940 - Phone
- (215) 860-3344
Quick Facts
- NPI
- 1730179854
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile